(19)
(11) EP 4 680 279 A1

(12)

(43) Date of publication:
21.01.2026 Bulletin 2026/04

(21) Application number: 24718949.1

(22) Date of filing: 12.03.2024
(51) International Patent Classification (IPC): 
A61K 39/395(2006.01)
C07K 16/28(2006.01)
A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 16/2803; C07K 16/2818; C07K 16/2809; C07K 16/2887; A61K 39/395; A61P 35/00; A61K 2039/505; A61K 2039/545; C07K 2317/31
 
C-Sets:
A61K 39/395, A61K 2300/00;
(86) International application number:
PCT/US2024/019506
(87) International publication number:
WO 2024/191983 (19.09.2024 Gazette 2024/38)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 13.03.2023 US 202363489808 P

(71) Applicant: Regeneron Pharmaceuticals, Inc.
Tarrytown, NY 10591-6706 (US)

(72) Inventors:
  • CHAUDHRY, Aafia
    Tarrytown, NY 10591 (US)
  • MOHAMED, Hesham
    Tarrytown, NY 10591 (US)

(74) Representative: J A Kemp LLP 
80 Turnmill Street
London EC1M 5QU
London EC1M 5QU (GB)

   


(54) METHODS OF TREATING CANCER WITH BISPECIFIC ANTI-CD22 X ANTI-CD28 MOLECULES